490 related articles for article (PubMed ID: 29578580)
61. Correlations Between Methionine Cycle Metabolism, COMT Genotype, and Polyneuropathy in L-Dopa Treated Parkinson's Disease: A Preliminary Cross-Sectional Study.
Andréasson M; Brodin L; Laffita-Mesa JM; Svenningsson P
J Parkinsons Dis; 2017; 7(4):619-628. PubMed ID: 28759974
[TBL] [Abstract][Full Text] [Related]
62. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.
Oliveri RL; Annesi G; Zappia M; Civitelli D; Montesanti R; Branca D; Nicoletti G; Spadafora P; Pasqua AA; Cittadella R; Andreoli V; Gambardella A; Aguglia U; Quattrone A
Neurology; 1999 Oct; 53(7):1425-30. PubMed ID: 10534246
[TBL] [Abstract][Full Text] [Related]
63. Smoking, genes encoding dopamine pathway and risk for Parkinson's disease.
Gu Z; Feng X; Dong X; Chan P
Neurosci Lett; 2010 Sep; 482(1):31-4. PubMed ID: 20603187
[TBL] [Abstract][Full Text] [Related]
64. Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.
Politi C; Ciccacci C; Novelli G; Borgiani P
Neuromolecular Med; 2018 Mar; 20(1):1-17. PubMed ID: 29305687
[TBL] [Abstract][Full Text] [Related]
65. Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.
Senek M; Nyholm D; Nielsen EI
Sci Rep; 2020 Oct; 10(1):18057. PubMed ID: 33093598
[TBL] [Abstract][Full Text] [Related]
66. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
Hamaue N; Ogata A; Terado M; Tsuchida S; Yabe I; Sasaki H; Hirafuji M; Togashi H; Aoki T
Brain Res; 2010 Jan; 1309():110-5. PubMed ID: 19879254
[TBL] [Abstract][Full Text] [Related]
67. Influence of COMT inhibition on levodopa pharmacology and therapy.
Goetz CG
Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519
[TBL] [Abstract][Full Text] [Related]
68. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
69. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
Heikkinen H; Nutt JG; LeWitt PA; Koller WC; Gordin A
Clin Neuropharmacol; 2001; 24(3):150-7. PubMed ID: 11391126
[TBL] [Abstract][Full Text] [Related]
70. Recent developments in the pharmacological treatment of Parkinson's disease.
Tuite P; Riss J
Expert Opin Investig Drugs; 2003 Aug; 12(8):1335-52. PubMed ID: 12882620
[TBL] [Abstract][Full Text] [Related]
71. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
[TBL] [Abstract][Full Text] [Related]
72. Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.
Finberg JPM
J Neural Transm (Vienna); 2019 Apr; 126(4):433-448. PubMed ID: 30386930
[TBL] [Abstract][Full Text] [Related]
73. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.
Sieradzan K; Channon S; Ramponi C; Stern GM; Lees AJ; Youdim MB
J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):51S-59S. PubMed ID: 7593732
[TBL] [Abstract][Full Text] [Related]
74. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
Müller T
Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
[TBL] [Abstract][Full Text] [Related]
75. Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.
Schneider F; Erisson L; Beygi H; Bradbury M; Cohen-Barak O; Grachev ID; Guzy S; Loupe PS; Levi M; McDonald M; Savola JM; Papapetropoulos S; Tracewell WG; Velinova M; Spiegelstein O
Br J Clin Pharmacol; 2018 Oct; 84(10):2422-2432. PubMed ID: 29959802
[TBL] [Abstract][Full Text] [Related]
76. Catechol-O-methyltransferase and Parkinson's disease.
Tai CH; Wu RM
Acta Med Okayama; 2002 Feb; 56(1):1-6. PubMed ID: 11873938
[TBL] [Abstract][Full Text] [Related]
77. Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype.
Williams-Gray CH; Hampshire A; Barker RA; Owen AM
Brain; 2008 Feb; 131(Pt 2):397-408. PubMed ID: 18178571
[TBL] [Abstract][Full Text] [Related]
78. New treatments for levodopa-induced motor complications.
Rascol O; Perez-Lloret S; Ferreira JJ
Mov Disord; 2015 Sep; 30(11):1451-60. PubMed ID: 26293004
[TBL] [Abstract][Full Text] [Related]
79. Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease.
Kakinuma S; Beppu M; Sawai S; Nakayama A; Hirano S; Yamanaka Y; Yamamoto T; Masafumi C; Aisihaer X; Aersilan A; Gao Y; Sato K; Sakae I; Ishige T; Nishimura M; Matsushita K; Satoh M; Nomura F; Kuwabara S; Tanaka T
eNeurologicalSci; 2020 Jun; 19():100239. PubMed ID: 32346620
[TBL] [Abstract][Full Text] [Related]
80. L-dopa therapy for Parkinson's disease: past, present, and future.
Nagatsua T; Sawadab M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
